Role of viral infections in the etiopathogenesis of systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Moroncini, Gianluca ^a,b   Mori, Simone ^a,b   Tonnini, Cecilia ^a,b   Gabrielli, Armando ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Cytomegalovirus (CMV); Parvovirus B19; Scleroderma virus; Systemic sclerosis

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; LEUKOTRIENE B4; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN NAG 2; PROTEIN UL94; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; APOPTOSIS; AUTOIMMUNITY; BLOOD VESSEL INJURY; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GAMMA IRRADIATION; HUMAN; HUMAN PARVOVIRUS B19; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; VIRUS INFECTION; IMMUNOLOGY; PARVOVIRUS INFECTION; VIROLOGY;

AUTOIMMUNITY; CYTOMEGALOVIRUS INFECTIONS; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; SCLERODERMA, SYSTEMIC;

EID: 84883768252     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. HARRIS ML, ROSEN A: Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003; 15: 778-84.
2. GABRIELLI A, AVVEDIMENTO EV, KRIEG T: Scleroderma. New Engl J Med 2009; 360: 1989-2003.
3. LITINSKY I, BALBIR A, ZISMAN D: Vaccination against influenza in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S7-11.
4. CASSISI G, SARZI-PUTTINI P, CAZZOLA M: Chronic widespread pain and fibromyalgia: could there be some relationships with infections and vaccinations?. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S118-26.
5. PRESCOTT RJ, FREEMONT AJ, JONES CJ, HOYLAND J, FIELDING P: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-63.
6. FLEISCHMAJER R, PERLISH JS: Capillary alterations in scleroderma. J Am Acad Dermatol 1980; 2: 161-70.
7. HARRISON NK, MYERS AR, CORRIN B et al.: Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706-13.
8. HOSKINS LC, NORRIS HT, GOTTLIEB LS, ZAMCHECK N: Functional and morphologic alterations of the gastrointestinal tract in progressive systemic sclerosis (scleroderma). Am J Med 1962; 33: 459-70.
9. FLEISCHMAJER R, PERLISH JS, WEST WP: Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977; 113: 1661-6.
10. FLEMING JN, NASH RA, McLEOD DO et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS One 2008; 3: e1452.
11. NIETO FJ, ADAM E, SORLIE P et al.: Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-7.
12. PANDEY JP, LEROY EC: Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 1998; 41: 10-5.
13. NEIDHART M, KUCHEN S, DISTLER O et al.: Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999; 42: 389-92.
14. HAMAMDZIC D, HARLEY RA, HAZEN-MARTIN D, LEROY EC: MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord 2001; 2: 3.
15. LEASK A, ABRAHAM DJ: TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
16. MICHELSON S, ALCAMI J, KIM SJ et al.: Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol 1994; 68: 5730-7.
17. DENGLER TJ, RAFTERY MJ, WERLE M, ZIMMERMANN R, SCHONRICH G: Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin- 1beta. Transplantation 2000; 69: 1160-8.
18. QIU H, STRAAT K, RAHBAR A, WAN M, SODERBERG-NAUCLER C, HAEGGSTROM JZ: Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. The J Exp Med 2008; 205: 19-24.
19. STREBLOW DN, SODERBERG-NAUCLER C, VIEIRA J et al.: The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999; 99: 511-20.
20. ZHOU YF, YU ZX, WANISHSAWAD C, SHOU M, EPSTEIN SE: The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun 1999; 256: 608-13.
21. OVERBEEK MJ, BOONSTRA A, VOSKUYL AE et al.: Platelet-derived growth factor receptorbeta and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosisassociated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. Arthritis Res Ther 2011; 13: R61.
22. BOLOVAN-FRITTS CA, SPECTOR SA: Endothelial damage from cytomegalovirus specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2008; 111: 175-82.
23. PAPAKOSTA D, MANIKA K, KYRIAZIS G: NK cell populations in collagen vascular disease. Clin Exp Rheumatol 2012; 5: 693-9.
24. CARVALHO D, SAVAGE CO, BLACK CM, PEARSON JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996; 97: 111-9.
25. BORDRON A, DUEYMES M, LEVY Y et al.: The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998; 101: 2029-35.
26. CHIZZOLINI C, RASCHI E, REZZONICO R et al.: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 1602-13.
27. DI ROSA F, BARNABA V: Persisting viruses and chronic inflammation: understanding their relation to autoimmunity. Immunol Rev 1998; 164: 17-27.
28. WUCHERPFENNIG KW, STROMINGER JL: Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
29. ZHAO ZS, GRANUCCI F, YEH L, SCHAFFER PA, CANTOR H: Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science (New York, NY) 1998; 279: 1344-7.
30. LUNARDI C, BASON C, NAVONE R et al.: Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6: 1183-6.
31. LUNARDI C, DOLCINO M, PETERLANA D et al.: Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Medicine 2006; 3: e2.
32. HUTT-FLETCHER LM, BALACHANDRAN N, ELKINS MH: B cell activation by cytomegalovirus. J Exp Med 1983; 158: 2171-6.
33. GABRIELLI A, SVEGLIATI S, MORONCINI G, AVVEDIMENTO EV: Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 2007; 19: 640-5.
34. BARZILAI O, RAM M, SHOENFELD Y: Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 2007; 19: 636-43.
35. VARANI S, CEDERARV M, FELD S et al.: Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol (Baltimore, Md.1950) 2007; 179: 7767-76.
36. MARSHAK-ROTHSTEIN A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35.
37. LAFYATIS R, YORK M: Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009; 21: 617-22.
38. YORK MR, NAGAI T, MANGINI AJ, LEMAIRE R, van SEVENTER JM, LAFYATIS R: A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007; 56: 1010-20.
39. SINZGER C, PLACHTER B, GREFTE A, THE TH, JAHN G: Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dise 1996; 173: 240-5.
40. RIEGLER S, HEBART H, EINSELE H, BROSSART P, JAHN G, SINZGER C: Monocytederived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000; 81: 393-9.
41. SODERBERG C, SUMITRAN-KARUPPAN S, LJUNGMAN P, MOLLER E: CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation 1996, 61: 594-600.
42. SODERBERG C, LARSSON S, ROZELL BL, SUMITRAN-KARUPPAN S, LJUNGMAN P, MOLLER E: Cytomegalovirus-induced CD13- specific autoimmunity-a possible cause of chronic graft-vs-host disease. Transplantation 1996, 61: 600-9.
43. FREDRICH R, TOYODA M, CZER LS et al.: The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385-391.
44. DUBEL L, FARGES O, JOHANET C, SEBAGH M, BISMUTH H: High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998; 65: 1072-5.
45. LONNQVIST B, RINGDEN O, WAHREN B, GAHRTON G, LUNDGREN G: Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984; 38: 465-8.
46. LARSSON K, ASCHAN J, REMBERGER M, RINGDEN O, WINIARSKI J, LJUNGMAN P: Reduced risk for extensive chronic graft-versushost disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reactionbased preemptive therapy against cytomegalovirus. Transplantation 2004; 77: 526-531.
47. BELL SA, FAUST H, MITTERMULLER J, KOLB HJ, MEURER M: Specificity of antinuclear antibodies in scleroderma-like chronic graftversus- host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 1996; 134: 848-854.
48. PASTANO R, DELL'AGNOLA C, BASON C et al.: Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. Int Immunol 2012; 24: 583-91.
49. POSTLETHWAITE AE, SHIGEMITSU H, KANANGAT S: Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004; 16: 733-8.
50. HU B, PHAN SH: Myofibroblasts. Curr Opin Rheumatol 2013; 25: 71-7.
51. SINZGER C, DIGEL M, JAHN G: Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 2008; 325: 63-83.
52. RAJKUMAR VS, HOWELL K, CSISZAR K, DENTON CP, BLACK CM, ABRAHAM DJ: Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005; 7: R1113-23.
53. ALCENDOR DJ, CHAREST AM, ZHU WQ, VIGIL HE, KNOBEL SM: Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J Neuroinflammation 2012; 9: 95.
54. FERRI C, ZAKRZEWSKA K, LONGOMBARDO G et al.: Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999; 17: 718-20.
55. FERRI C, GIUGGIOLI D, SEBASTIANI M et al.: Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: comment on the article by Ray et al. Arthritis Rheum 2002; 46: 2262-3 author reply 2263-4.
56. ZAKRZEWSKA K, CORTIVO R, TONELLO C et al.: Human parvovirus B19 experimental infection in human fibroblasts and endothelial cells cultures. Virus Res 2005; 114: 1-5.
57. MAGRO CM, NUOVO G, FERRI C, CROWSON AN, GIUGGIOLI D, SEBASTIANI M: Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol 2004; 31: 43-50.
58. FERRI C, AZZI A, MAGRO CM: Parvovirus B19 and systemic sclerosis. Br J Dermatol 2005; 152: 819-20.
59. MEYER O: Parvovirus B19 and autoimmune diseases. Joint Bone Spine: revue du rhumatisme 2003; 70: 6-11.
60. Von LANDENBERG P, LEHMANN HW, MODROW S: Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmunity Reviews 2007; 6: 278-85.
61. LEHMANN HW, PLENTZ A, VON LANDENBERG P, KUSTER R-M, MODROW S: Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies. Clin Rheumatol 2008; 27: 333-8.
62. LUNARDI C, TISO M, BORGATO L et al.: Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998; 28: 936-48.
63. DISTLER O, DISTLER JH, SCHEID A et al.: Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109- 16.
64. DAVIES CA, JEZIORSKA M, FREEMONT AJ, HERRICK AL: The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006; 37:190-7.
65. KUWANA M, OKAZKI Y, YASUOKA H, KAWAKAMI Y, IKEDA Y: Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10.
66. CIPRIANI P, GUIDUCCI S, MINIATI I et al.: Impairment of endothelial differentiation from bone marrow-derived mesenchymal stem cells: new insights into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007; 56:1994-2004.
67. FLEMING JN, NASH RA, McLOAD DO et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS One 2008; 3: e1452-e1452.
68. SCHEJA A, WILDT M, WOLLHEIM FA et al.: Circulating collagen metabolites in systemic sclerosis: differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 2000; 39: 1110-1113.
69. TAICHMAN RS, NASSIRI MR, REILLY MJ, PTAK RG, EMERSON SG, DRACH JC: Infection and replication of human cytomegalovirus in bone marrow stromal cells: effects on the production of IL-6, MIP-1alpha, and TGF-beta1. Bone Marrow Transplant 1997; 19: 471-80.
70. BROWN KE, YOUNG NS: Parvoviruses and bone marrow failure. Stem Cells (Dayton, Ohio) 1996; 14: 151-63.
71. SIMMONS P, KAUSHANSKY K, TOROKSTORB B: Mechanisms of cytomegalovirusmediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci USA 1990; 87: 1386-90.
72. NEVSKAYA T, BYKOVSKAIA S, LYSSUK E et al.: Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol 2008; 26: 421-9.
73. MOK MY, YIU KH, WONG CY et al.: Low circulating level of CD133+KDR+cells in patients with systemic sclerosis. Clin Exp Rheumatol 2010; 28: S19-25.
74. MANETTI M, GUIDUCCI S, IBBA-MANNESCHI L, MATUCCI-CERINIC M: Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010; 14: 1241-54.
75. VIRGIN HW, WHERRY EJ, AHMED R: Redefining chronic viral infection. Cell 2009; 138: 30-50.
76. DELWART E: A roadmap to the human virome. PLoS Pathogens 2013; 9: e1003146.
77. SOHN S, LEE ES, BANG D: Learning from HSV-infected mice as a model of Behçet's disease. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S96-103.
78. CADWELL K, PATEL KK, MALONEY NS et al.: Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010; 141: 1135-45.
79. ROMANO E, MANETTI M, GUIDUCCI S, CECCARELLI C, ALLANORE Y, MATUCCI-CERINIC M: The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S75-86.
80. GETTS MT, MILLER SD: 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 2010; 160: 15-21.